Last reviewed · How we verify
NCT03853733
Hypofractionated Palliative Radiotherapy in Patients With Advanced Non-operable Rectal Cancer
trial testing rectal cancer radiotherapy in Rectal Cancer in 50 participants. Currently enrolling.
1 March 2027
Quick facts
| Lead sponsor | Consorci Sanitari de Terrassa |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 October 2016 |
| Primary completion | 1 March 2027 |
| Estimated completion | 1 March 2027 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- rectal cancer radiotherapy
Conditions studied
- Rectal Cancer — all drugs for Rectal Cancer →
Sponsor
Consorci Sanitari de Terrassa — full company profile →
Who can join
18 and older, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Many patients with rectal cancer were not candidates for surgical resection because advanced age, comorbidities, or multiple synchronous metastases. In this scenario only comfort measures or different palliative radiotherapy regimens are applied, from single doses to treatments lasting several weeks. The aim of this prospective study is to describe the preliminary results of our protocol of hypofractionated palliative radiotherapy in patients with non-operable rectal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03853733
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Cancer
Currently open trials in the same condition.
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
- NCT07501845 — Registry Maastro Applicator · recruiting
- NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
- NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting
Other Consorci Sanitari de Terrassa trials
Trials by the same sponsor.
- NCT07467408 — Treatment of Mechanical Low Back Pain With High-Intensity Focused Ultrasound (HIFU) · not yet recruiting
- NCT07210892 — Paramedian Incidence Angles in Spinal Anaesthesia · recruiting
- NCT06956794 — Multimodal Training With Immersive Virtual Reality to Improve the Cognitive Health and Emotional Well-being of Older Wom · NA · active not recruiting
- NCT06713460 — Emotional Intelligence Intervention to Improve Mental Well-Being of Adolescents With Emotional Distress (BEAM) · NA · recruiting
- NCT07040748 — Immersive Virtual Reality Training for Improving Cognition in Adults With Metabolic Syndrome · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03853733 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Consorci Sanitari de Terrassa
- Last refreshed: 19 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03853733.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing